The short answer: This episode summarizes three items from September 2026: two phase 3 retatrutide trials, an oral GLP-1 trial in early type 2 diabetes, and a pooled analysis of lifestyle programs by prediabetes phenotype. Each entry gives the design, sponsor, absolute numbers as reported, and limits.
The Queue is Metabolic Media’s running research roundup. Each entry is a summary, not medical advice. We say when we could read only an abstract, and we name the funder of every study. Most drug trials below were paid for by the drug’s developer. Episode 1 covers items published September 14-29, 2026, a wider window than later weekly episodes. Research current as of Sept 30, 2026, based on items found through that date.
Research
Retatrutide in two phase 3 trials (TRIUMPH-1 and TRIUMPH-2)
Source: TRIUMPH-2, The Lancet, published Sept 29, 2026 (DOI 10.1016/S0140-6736(26)01861-1). TRIUMPH-1, New England Journal of Medicine, online Sept 29, 2026 (DOI 10.1056/NEJMoa2604169). We read the journal abstracts only (Sept 30, 2026); the figures below are abstract-level and were not checked against the full papers.
Design: Both are randomized, double-blind, placebo-controlled phase 3 trials lasting 80 weeks. Both were sponsored and funded by Eli Lilly, the drug’s maker. We did not review the authors’ disclosure statements.
Who was studied: TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and a BMI of 27 or higher (mean age 55.1; mean BMI 38.2). TRIUMPH-1 randomized 2,339 adults with obesity and no diabetes; the sleep-apnea and knee-osteoarthritis groups were subsets.
What they found: In TRIUMPH-2 (treatment-regimen estimand), mean body weight changed by -18.8% in the highest-dose group versus -5.1% with placebo at week 80. Diarrhea occurred in 34% versus 13%, and nausea in 28% versus 8%. In TRIUMPH-1 (treatment-regimen estimand, intention-to-treat), weight changed by -25.0% in the highest-dose group versus -3.9% with placebo. In the 243 participants with obstructive sleep apnea, breathing-interruption events per hour fell by 32.1 versus 9.6 with placebo (intention-to-treat). In the 574 participants with knee osteoarthritis, the pain score fell 4.1 versus 2.5 points (intention-to-treat).
Limits: Both trials were sponsor-run and measured weight and lab values, not heart attacks, strokes, or deaths. Eighty weeks is short for a long-term condition. The sleep-apnea and knee subgroups are small subsets of the full trials.
What this does NOT show: Whether weight stays lower after treatment stops, because these abstracts report no withdrawal data. It does not show effects on heart disease, kidney disease, or survival, long-term safety, or how this drug compares with any other, because each trial compared it only with placebo.
An oral GLP-1 drug in early type 2 diabetes (OUTSTAND-1)
Source: Nature Medicine, Sept 29, 2026 (open access; DOI 10.1038/s41591-026-04651-9; ClinicalTrials.gov NCT06672172). Full text read.
Design: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial at 46 sites in China. Funded by Jiangsu Hengrui Pharmaceuticals, the drug’s developer; six authors are employees and three declare a pending patent related to the drug.
Who was studied: 284 adults with type 2 diabetes managed with diet and exercise alone (mean age 49.4; 33.1% women; mean A1c 7.95%; median diabetes duration 1.6 years; all Asian).
What they found: At week 32 (treatment-policy estimand), A1c was 1.20 to 1.45 percentage points lower than with placebo across the three dose groups. A1c was under 7.0% in 71.4% to 77.8% of participants versus 25.0% with placebo. Body weight differed from placebo by -0.65% (not statistically significant), -2.23%, and -3.56% across dose groups. Gastrointestinal adverse events occurred in 44.3%, 60.0%, and 73.6% of dose groups versus 15.3% with placebo; adverse events led to stopping in 1.4%, 2.9%, and 6.9% versus 0%.
Limits: All participants were Chinese. The trial was built to measure blood glucose, not rare side effects or heart and kidney outcomes. The placebo group switched to the drug after week 32, and the authors saw some loss of the A1c effect and partial weight regain between weeks 32 and 52.
What this does NOT show: Long-term safety or durability, or effects on heart attacks, strokes, or kidney failure. It does not show results in people of other ancestry, with higher BMI, longer diabetes duration, or on other medicines. The authors say cross-trial comparisons provide context rather than evidence of comparative efficacy.
Lifestyle programs by prediabetes phenotype (pooled analysis)
Source: James E, Henson J, Davies MJ, Khunti K, Yates T. Diabetologia, Sept 14, 2026 (open access; DOI 10.1007/s00125-026-06873-5). We read the open-access full text (Sept 30, 2026).
Design: A post hoc pooled analysis of three randomized trials (Let’s Prevent Diabetes, Walking Away, and PROPELS) comparing group-based lifestyle programs with usual care for up to 48 months. Funded by the UK National Institute for Health and Care Research. Three of the five authors report industry consulting, advisory, speaking, or research funding, including from Eli Lilly and Novo Nordisk; details are in the paper’s disclosure section.
Who was studied: 2,150 adults at risk of type 2 diabetes (mean age 63-65), grouped by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), both, or normal glucose.
What they found: Compared with usual care, steps per day rose by 808 (95% CI 402 to 1,213) in the IFG-plus-IGT group, 523 (229 to 818) in the IGT group, and 247 (4 to 491) in the normal-glucose group. The isolated-IFG group showed no detectable change (71 steps; 95% CI -429 to 571). Two-hour glucose fell 0.5 mmol/L (95% CI -0.9 to 0.0) in the IFG-plus-IGT group only.
Limits: The trials were not designed for this question. Program lengths differed, not everyone had data at every time point, and the estimate for the isolated-IFG group was imprecise, as its wide confidence interval shows. The outcome was steps per day, not diabetes.
What this does NOT show: Whether any group developed or avoided type 2 diabetes. It does not show that walking more caused the glucose change; the authors describe that link as speculated. It says nothing about people outside these UK trials, who were mostly of White European ancestry.
What we left out
The Queue skips compounded-drug news, price and coverage news, and results that exist only as conference presentations or press releases. For Episode 1 that includes the orforglipron cardiovascular-safety trial (ACHIEVE-4) presented at EASD, which we could not match to a peer-reviewed record, and two industry combination-therapy presentations at the same meeting.
How to read a study summary
A randomized trial uses chance to assign treatments, which limits bias. An observational study compares people as they happened to be treated, so other differences can explain a result. “Placebo-adjusted” means the placebo group’s change is subtracted. A hazard ratio is a relative measure of how often an event happens, not the chance of it happening to one person.
Frequently asked questions
What does “non-inferior” mean in a trial?
It means a treatment was shown to be not worse than a comparison by more than a pre-set margin. It does not show the treatment is better.
What is the difference between a randomized trial and an observational study?
In a randomized trial, chance decides who gets which treatment, which limits bias. In an observational study, people are compared as they happened to be treated, so other differences between groups can explain the result.
Does this episode tell me what to take or what to ask my clinician?
No. The Queue summarizes published research; it does not give medical advice, dosing, or treatment guidance.
Sources
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet, published Sept 29, 2026. DOI 10.1016/S0140-6736(26)01861-1. ClinicalTrials.gov NCT05929079. Sponsor: Eli Lilly. (Abstract read.)
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med, online Sept 29, 2026. DOI 10.1056/NEJMoa2604169. ClinicalTrials.gov NCT05929066. Sponsor: Eli Lilly. (Abstract read.)
- Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Nature Medicine, Sept 29, 2026. DOI 10.1038/s41591-026-04651-9. ClinicalTrials.gov NCT06672172. Funding: Jiangsu Hengrui Pharmaceuticals.
- James E, Henson J, Davies MJ, Khunti K, Yates T. Differential physical activity responses to diabetes risk reduction interventions according to prediabetes phenotype in at-risk individuals: pooled analysis from three randomised controlled trials. Diabetologia, Sept 14, 2026. DOI 10.1007/s00125-026-06873-5. PubMed 42736402. Funding: NIHR.
This article is for general education. It isn’t a substitute for personal medical advice. If you have questions about your health or a study’s relevance to you, talk with a licensed clinician who knows your health history.
Disclosure: Metabolic Media is an independent educational publisher. We may have a financial affiliation with some entities featured on this site. Rank positions are determined by our published methodology. We do not provide medical care, diagnoses, or treatment.
Medical disclaimer: Content on Metabolic Media is for educational purposes only and is not medical advice, diagnosis, or treatment. We are not a medical provider, pharmacy, or telehealth clinic. Always consult a licensed clinician. If you have a medical emergency, call 911 (US) or your local emergency number.